Domain Therapeutics today announced the signing of a research and license collaboration agreement with Boehringer Ingelheim. This agreement deals with Orphan Protein Coupled Receptors (GPCRs) in the central nervous system (CNS) field. Domain Therapeutics, a French biopharmaceutical company specializing in the discovery and development of molecules targeting GPCRs in CNS diseases, oncology and immuno-oncology will combine its expertise with that of Boehringer Ingelheim in discovery and development Clinic of drugs in many indications.
Domain Therapeutics will use DTect-All and its proprietary differentiating platform, bioSens-All , to screen and characterize compounds with high potential. In addition to its internal team, Domain will rely on this collaboration on a network of recognized experts in RCPGs (Prof. Brigitte Kieffer (Douglas Institute – Montreal, Canada) and Prof Michel Bouvier (IRIC – Montreal, Canada)), who provide additional knowledge and insight into the research phases.
Domain will receive a payout upon signing, and then will be eligible for milestone payments for research, development and marketing as well as royalties on sales. Financial details were not disclosed.
“We are excited to begin this collaboration with Domain Therapeutics, a key player in the field of GPCRs. This agreement will help us strengthen our research efforts in the CNS, “says Dr. Bernd Sommer, Head of Central Nervous System Disease Research. “Domain is a quality partner with complementary expertise and key technologies that will enable us to accelerate research and development in this field where medical needs are considerable. ”
“We are excited to be working with Boehringer Ingelheim, who is interested in scientific innovation and the drugs of tomorrow,” says Pascal Neuville, Managing Director of Domain Therapeutics. “Our approach and technologies will help identify new drug candidates for these challenging targets, and with the strength and expertise of Boehringer Ingelheim, we can move them quickly to the clinic. ”
About G-Protein Coupled Receptors
GPCRs belong to the family of membrane receptors and are the main class of therapeutic targets for many indications. The binding of a specific hormone or ligand to the receptor binding site activates one or more intracellular signaling pathways. This allows the cell to provide a response adapted to changes in its environment. GPCR drugs account for about 40% of market drugs, but only 15% of GPCRs are used. As a result, GPCRs remain largely underutilized to date.
These receptors are widely expressed in the central nervous system where they play a detrimental role in the regulation of brain function. A significant proportion of GPCRs are orphaned, with no known ligand, which complicates efforts to discover new drugs. Targets of this complexity are not addressable with conventional R & D approaches and require adapted technologies.
About Domain Therapeutics
Domain Therapeutics is a profitable biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting membrane receptors and more specifically GPCRs, one of the most important drug target classes.
Domain identifies and develops candidates (allosteric modulators, biased ligands) through its innovative approaches and technologies. The company relies on a business model with three sources of revenue: 1) collaborations with pharmaceutical companies to discover new molecules, 2) the licensing of bioSens-All , 3) the creation of single-product companies for the development of its internal pipeline of preclinical candidates for central nervous system diseases and cancer. These single-product companies attract investors to develop their product. The exit is through the acquisition of the company when it arrives at the planned inflection point.
http://www.domaintherapeutics.com (link is external)